Missouri sues 19 PBMs and insulin makers over alleged pricing scheme

By ··2 min read

Missouri Attorney General Catherine Hanaway has sued 19 pharmacy benefit manager and drug manufacturer defendants, alleging a scheme to inflate insulin prices in violation of the Missouri Merchandising Practices Act. The state seeks injunctive relief, restitution, damages and disgorgement.

Missouri Attorney General Catherine Hanaway announced on January 15, 2026, that her office had filed suit in St. Louis County Circuit Court against 19 pharmacy benefit manager and drug manufacturer defendants, alleging a scheme to manipulate the state's healthcare markets and inflate the price of insulin. The petition seeks a declaration that the conduct is unlawful, a permanent injunction, and restitution, damages and disgorgement for affected Missouri consumers. No total dollar figure was specified.

The defendants include Express Scripts entities and parent Evernorth Health; CVS Health, CVS Pharmacy and Caremark entities; UnitedHealth Group, Optum and OptumRx entities; Medco Health Solutions; and manufacturers Eli Lilly and Company, Novo Nordisk Inc. and Sanofi-Aventis U.S. LLC. The attorney general's office alleges violations of Section 301.210 RSMo and the Missouri Merchandising Practices Act, which prohibits deceptive and unfair business practices, as well as Missouri common law including unjust enrichment. The state alleges that Missouri diabetics rely on PBMs to secure the lowest insulin prices and build formularies that improve health, but were instead exposed to artificially inflated list prices. The office said manufacturers published prices of $300 to $400 in Missouri for drugs sold abroad for the equivalent of less than $5, and that roughly 18 per cent of the state's nearly 450,000 uninsured residents are diabetic.

The attorney general's announcement did not include responses from any of the defendants.

Missouri's suit is notable because Express Scripts, the largest PBM defendant, is headquartered in the state. The case joined a cluster of state actions filed in January 2026, including Oregon's $900 million insulin lawsuit and a separate Iowa action. It also tracks the theory of the FTC's 2024 administrative case against the three largest PBMs, which alleged that rebate-driven formulary practices inflated insulin list prices.

The case was filed in state court and the petition has been published. Defendants in similar state insulin cases have frequently sought removal to federal court and transfer to the national insulin pricing multidistrict litigation.

Cite this report

The Precedent. "Missouri sues 19 PBMs and insulin makers over alleged pricing scheme." August 31, 2026. https://theprecedent.org/article/missouri-sues-19-pbms-and-insulin-makers-over-alleged-pricing-scheme